Synapse - Genitourinary Oncology Service

Results (121)

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes

Journal Article

Autio, K. A.; Kyriakopoulos, C. E.; Palyca, P.; Xiao, H.; Emamekhoo, H.; Danila, D.; Jan, M.; Catharine, V.; Riedel, E.; Devitt, M.; more...
Investigational New Drugs (2025)

Fulltext@MSK | Save

Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: A phase I study

Journal Article

Stein, M. N.; Vinceneux, A.; Robbrecht, D.; Doger, B.; Autio, K. A.; Schweizer, M. T.; Calvo, E.; Medina, L.; Van Dongen, M.; Deville, J. L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer

Journal Article

Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
Journal of Immunotherapy and Precision Oncology (2025)

Fulltext@MSK | Save

Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer

Meeting Abstract

McManus, H. D.; Howard, L.; Crowell, K. A.; Hyslop, T.; Autio, K. A.; Rathkopf, D.; Dreicer, R.; Chi, K. N.; Ong, M.; Mateo, J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer

Journal Article

Galsky, M. D.; Autio, K. A.; Cabanski, C. R.; Wentzel, K.; Graff, J. N.; Friedlander, T. W.; Howes, T. R.; Shotts, K. M.; Densmore, J.; Spasic, M.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer

Journal Article

Ridouani, F.; Vargas, H. A.; Holzwanger, D. J.; Schöder, H.; Waters, E.; Petre, E. N.; Martin, A.; Satagopan, J.; Gonen, M.; Autio, K. A.; more...
European Urology Oncology (2025)

Fulltext@MSK | Save

Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Meeting Abstract

Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer

Journal Article

Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer

Journal Article

Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Pain and its association with survival for Black and White individuals with advanced prostate cancer in the United States

Journal Article

Rencsok, E. M.; Slopen, N.; McManus, H. D.; Autio, K. A.; Morgans, A. K.; McSwain, L.; Barata, P.; Cheng, H. H.; Dreicer, R.; Gerke, T.; more...
Cancer Research Communications (2024)

Fulltext@MSK | Save